Jinling Pharmaceutical Corporation Limited announced that phloroglucinol orally disintegrating tablets, jointly developed with its related party Nanjing Adicaiteng Biomedical Limited Liability Company, have been approved by the National Medical Products Administration and obtained a drug registration certificate. The specification is 80 milligrams, and the registration classification is Category 3 chemical drug. The marketing authorization holder for the drug is Adicaiteng, and production is the responsibility of Nanjing Jinling Pharmaceutical Factory under Jinling Pharmaceutical. The project was reviewed and approved by the board of directors in August 2023 and accepted in October 2024. The company stated that this approval will help improve its product structure, but subsequent production and sales arrangements have not yet been agreed with Adicaiteng under a specific agreement, and there is uncertainty. It reminded investors to pay attention to risks.
Jinling Pharmaceutical Co LtdJinling Pharmaceutical obtained a drug registration certificate for phloroglucinol orally disintegrating tablets, improving its product structure.
Adicaiteng is the marketing authorization holder for the newly approved phloroglucinol orally disintegrating tablets.
